Hoechst Pakistan Past Earnings Performance
Past criteria checks 4/6
Hoechst Pakistan has been growing earnings at an average annual rate of 22%, while the Pharmaceuticals industry saw earnings growing at 2.5% annually. Revenues have been growing at an average rate of 12.7% per year. Hoechst Pakistan's return on equity is 26.9%, and it has net margins of 6.2%.
Key information
22.0%
Earnings growth rate
22.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 12.7% |
| Return on equity | 26.9% |
| Net Margin | 6.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hoechst Pakistan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 26,006 | 1,619 | 4,117 | 0 |
| 30 Jun 24 | 24,652 | 1,709 | 3,878 | 0 |
| 31 Mar 24 | 22,894 | 1,054 | 3,547 | 0 |
| 31 Dec 23 | 21,369 | 361 | 3,461 | 0 |
| 30 Sep 23 | 20,394 | -99 | 3,520 | 0 |
| 30 Jun 23 | 19,084 | -544 | 3,260 | 0 |
| 31 Mar 23 | 18,939 | -405 | 3,374 | 0 |
| 31 Dec 22 | 18,560 | 167 | 3,365 | 0 |
| 30 Sep 22 | 18,006 | 770 | 3,115 | 0 |
| 30 Jun 22 | 17,334 | 651 | 3,006 | 0 |
| 31 Mar 22 | 16,687 | 875 | 2,714 | 0 |
| 31 Dec 21 | 15,881 | 906 | 2,444 | 0 |
| 30 Sep 21 | 15,350 | 848 | 2,656 | 0 |
| 30 Jun 21 | 15,562 | 1,040 | 2,507 | 0 |
| 31 Mar 21 | 14,265 | 823 | 2,414 | 0 |
| 31 Dec 20 | 14,108 | 493 | 2,551 | 0 |
| 30 Sep 20 | 14,277 | 200 | 2,377 | 0 |
| 30 Jun 20 | 13,874 | 122 | 2,556 | 0 |
| 31 Mar 20 | 14,330 | -52 | 2,815 | 0 |
| 31 Dec 19 | 14,501 | 155 | 2,848 | 0 |
| 30 Sep 19 | 13,763 | -27 | 2,737 | 0 |
| 30 Jun 19 | 13,434 | -62 | 2,750 | 0 |
| 31 Mar 19 | 13,232 | 467 | 2,632 | 0 |
| 31 Dec 18 | 12,961 | 613 | 2,589 | 0 |
| 30 Sep 18 | 12,777 | 647 | 2,617 | 0 |
| 30 Jun 18 | 12,587 | 998 | 2,512 | 0 |
| 31 Mar 18 | 12,728 | 963 | 2,559 | 0 |
| 31 Dec 17 | 12,446 | 1,006 | 2,495 | 0 |
| 30 Sep 17 | 12,210 | 1,360 | 2,474 | 0 |
| 30 Jun 17 | 12,804 | 1,389 | 2,401 | 0 |
| 31 Mar 17 | 12,279 | 1,306 | 2,408 | 0 |
| 31 Dec 16 | 11,890 | 1,019 | 2,394 | 0 |
| 30 Sep 16 | 11,906 | 564 | 2,503 | 0 |
| 30 Jun 16 | 11,075 | 190 | 2,590 | 0 |
| 31 Mar 16 | 11,192 | -41 | 2,526 | 0 |
| 31 Dec 15 | 10,786 | 66 | 2,465 | 0 |
| 30 Sep 15 | 10,628 | 251 | 2,326 | 0 |
| 30 Jun 15 | 10,425 | 328 | 2,224 | 0 |
| 31 Mar 15 | 9,937 | 294 | 2,164 | 0 |
| 31 Dec 14 | 9,949 | 238 | 2,093 | 0 |
| 30 Sep 14 | 9,725 | 274 | 1,942 | 0 |
| 30 Jun 14 | 9,307 | 243 | 1,899 | 0 |
| 31 Mar 14 | 9,166 | 369 | 1,786 | 0 |
| 31 Dec 13 | 8,792 | 310 | 1,695 | 0 |
Quality Earnings: HPL has high quality earnings.
Growing Profit Margin: HPL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HPL has become profitable over the past 5 years, growing earnings by 22% per year.
Accelerating Growth: HPL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: HPL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.1%).
Return on Equity
High ROE: HPL's Return on Equity (26.9%) is considered high.